First participant enrolled on the “Mobile PSA Screening Clinic & Community Health Cohort”— years in the making and a huge milestone for our innovative approach to research in the community with “precision outreach” Nima Sharifi Desai Sethi Urology Institute Sylvester Comprehensive Cancer Center

In a daze after short trip to #Medellín, #Guatapé & La Piedra, Colombia 🇨🇴. Warm people, incredible sights and dizzying array of tropical fruits! Chontaduro is a welcome addition to my gustatory vocabulary. What a splendid experience! Gracias por compartir ustedes país conmigo!

🧬🧬🧬Enzalutamide boosts OS and rPFS in mHSPC patients regardless of HSD3B1 genotype. While clinical outcomes are similar across genotypes, the AP genotype shows higher post-progression mortality and TEAEs. Enzalutamide remains effective in mHSPC independent of HSD3B1 status.

Nima Sharifi Duke Cancer One conclusion here is clearly that ADT alone is insufficient for mHSPC patients and an ARPI can rescue these poor outcomes, as really all genotype groups benefited. The differences in fracture rate and gynecomastia by genotype are really intriguing! DCI Center for Prostate & Urologic Cancers

How to Find the Right Oncologist for You nytimes.com/2024/08/22/wel…

Thank you Brian Rini, MD and Tom Powles for inviting me to discuss prostate cancer hormonal therapy resistance on Uromigos! podcasters.spotify.com/pod/show/the-u…

Take a listen to the latest Uromigos #podcast featuring Nima Sharifi discussing mechanisms of resistance to hormone therapy in #prostatecancer. podcasts.apple.com/us/podcast/the…

For ASH members. Im supporting Mikkael A. Sekeres MD, MS for ASH Secretary. He’s a leader in the field. A champion of changes to ABIM MOC. Please vote and support at: vote.escvote.com/ash

Quién cantó los Cinco Centavitos originales?

Six genes involved in androgen production/ uptake/ conversion (APUC) distinguish ligand-driven PCa from AR-driven PCa, and have unique clinical outcomes. Congrats to Justin Hwang and his team. Nima Sharifi Charles Ryan Caris Life Sciences insight.jci.org/articles/view/…

TY Emmanuel Antonarakis -Androgen production still has a lot to reveal- a target rich environment - The "APUC6" may be the key drivers of a high ligand production, low AR prostate cancer. More to follow...hopefully translation! congrats Hannah, JUstin and team Masonic Cancer Center, University of Minnesota Caris Life Sciences

Online now: HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES dlvr.it/TCmph5